A new era for venous thromboembolism prevention in medical inpatients

Editorial Focus on: Mahan et al. Thromb Haemost 2014; 112: 692-699.

• References

• 1 Collins R, Scrimgeour A, Yusuf S. et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-1173.
• 2 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med 1989; 82: 203-205.
• 3 Kahn SR, Lim W, Dunn AS. et al. Prevention of VTE in Nonsurgical Patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 Suppl e195S-e226S.
• 4 Mismetti P, Laporte-Simitsidis S, Tardy B. et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-19.
• 5 Hull RD, Schellong SM, Tapson VF. et al. EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153: 8-18.
• 6 Goldhaber SZ, Leizorovicz A, Kakkar AK. et al. ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-2177.
• 7 Cohen AT, Spiro TE, Büller HR. et al. MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513-523.
• 8 Violi F, Perri L, Loffredo L. Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials. Thromb Haemost 2013; 109: 589-595.
• 9 Ageno W, Squizzato A, Ambrosini F. et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-750.
• 10 Gussoni G, Campanini M, Silingardi M. et al. In hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine. Findings from a multicenter, prospective study. Thromb Haemost 2009; 101: 893-901.
• 11 Cohen AT, Tapson VF, Bergmann JF. et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 37: 387-394. Erratum in: Lancet 2008; 371: 1914.
• 12 Bozzato S, Squizzato A, Donadini MP. et al. Patient selection for thromboprophylaxis in medical inpatients. Expert Rev Cardiovasc Ther 2013; 11: 1639-1647.
• 13 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J Thromb Haemost 2010; 8: 2450-2457.
• 14 Decousus H, Tapson VF, Bergmann JF. et al. Factors at admission associated with bleeding risk in medical patients. Findings from the IMPROVE Investigators. Chest 2011; 139: 69-79.
• 15 Nendaz M, Spirk D, Kucher N. et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost 2014; 111: 531-538.
• 16 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112: 692-699.
• 17 Tapson VF, Decousus H, Pini M. et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007; 132: 936-945.
• 18 McGinn TG, Guyatt GH, Wyer PC. et al. Users’ guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. J Am Med Assoc 2000; 284: 79-84.
• 19 Cohen AT, Spiro TE, Spyropoulos AC. et al. MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014; 12: 479-487.
• 20 Mebazaa A, Spiro TE, Büller HR. et al. Predicting the Risk of Venous Thromboembolism in Patients Hospitalized with Heart Failure. Circulation. 2014 Epub ahead of print.
• 21 Cohen AT, Harrington R, Goldhaber SZ. et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J 2014; 167: 335-341.
• 22 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients, NCT02111564). Available at: http://clinicaltrials.gov/show/NCT02111564
• 23 VTE calculator. Available at: https://itunes.apple.com/it/app/vte-calculator/id730418540?mt=8 .